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Aim: This	 study	examined	 the	 influence	of	different	human	milk	 fortifiers	on	bio‐
markers	of	gastrointestinal	immaturity	and	inflammation	in	preterm	infants.
Methods: We	 report	 secondary	 outcomes	 from	 a	 controlled,	 double‐blind,	 ran‐
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1  | INTRODUC TION
Preterm	infants	have	immature	development	at	birth1 and are more 
















Maturity	 of	 gastrointestinal	 function	 and	 inflammation	 can	 be	
assessed	using	faecal	biomarkers,	which	provide	a	non‐invasive	and	
early	method	for	detecting	any	increased	risk	for	these	conditions.9 




blood	 proteins	 into	 the	 intestinal	 tract.10	 This	 process	 happens	 in	












milk	 fortifiers	with	 different	 composition	 on	 faecal	 biomarkers	 of	






was	FM85	Human	Milk	 Fortifier	 (Nestlé,	Vevey,	 Switzerland).	 The	
primary	results	of	the	trial	have	already	been	reported.15,16	Briefly,	
they	showed	that	the	unadjusted	weight	gain	rate	was	18.3	g/kg/d	
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This	 report	 presents	 secondary	 outcomes	 from	 a	 controlled,	 dou‐
ble‐blind,	 randomised,	 parallel	 group	 study	 that	was	 conducted	 in	
neonatal	intensive	care	units	at	11	metropolitan	hospitals	in	France,	












drate	 and	 a	 blend	of	micronutrients.	 The	new	 fortifier	was	devel‐








Infants	 tolerating	 ≥100	mL/kg/d	 of	 human	milk	 for	 >24	 hours	





fortification	being	 reached	when	 infants	could	maintain	 intakes	of	
150‐180	mL/kg/d,	 namely	 full	 enteral	 feeds	 and	 full	 fortification.	
This	was	called	study	day	one	and	occurred	approximately	3	days	
after	 fortification	 began.	 The	 measurements	 then	 continued	 for	
another	21	days.	 FS	day	one	occurred	 at	 a	median	 (Q1‐Q3)	of	 13	




Stool	 samples	 were	 collected	 on	 FS	 day	 one	 or	 the	 day	 after	
and	at	21	±	1	days	 (day	21).	They	were	analysed	for	 the	following	
parameters:	 gastrointestinal	 inflammation,	 namely	 faecal	 alpha‐1	
antitrypsin,	calprotectin	and	total	protein,	and	maturity	of	gut	func‐
tion,	 namely	 faecal	 elastase‐1.	Approximately	 5‐8	 g	was	 collected	
from	 each	 infant	 within	 2	 hours	 of	 a	 bowel	 movement.	 Samples	
were	 stored	 frozen	 at	 −20°C	 and	 shipped	 for	 analysis	 on	 dry	 ice.	
If	the	stool	sample	quantity	was	below	5.5	g,	which	was	judged	to	




faecal	 extraction	 device	 (Roche	 Diagnostics).	 These	 were	 as	 fol‐
lows:	EK‐Cal	 (Bühlmann	Laboratories);	ScheBo	Pancreatic	Elastase	
1	 (ScheBo	Biotech	AG)	 and	Euroimmun	Analyzer	A1	 (Euroimmun).	
Faecal	 alpha‐1	 antitrypsin	 concentration	 was	 assessed	 by	 immu‐
nonephelometry,	 using	 the	 IMMAGE	 800	 (Beckman	 Coulter)	 and	





















tal	 demographics	 have	previously	 been	 reported.15	A	 total	 of	 153	















were	 significantly	 lower	 in	 the	 new	 fortifier	 group	 compared	 to	
the	 control	 fortifier	 group	at	 study	day	21	 (P = .010	and	 .016,	 re‐
spectively).	 In	addition,	the	increase	from	FS	day	one	to	study	day	
21	 for	 both	of	 these	parameters	was	 significantly	 less	 in	 the	 new	
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fortifier	group	compared	to	the	control	fortifier	group	(P = .007 and 
.004,	 respectively).	 Faecal	 calprotectin	 concentrations	 (Figure	 2B)	
tended	to	increase	in	both	groups	during	the	study,	according	to	the	
























human	milk19,20	 and	appears	 to	 increase	with	 lactation.19	Human	
milk	 alpha‐1	 antitrypsin	 is	 also	 resistant	 to	 pasteurisation21 and 
proteolysis	 in	 young	 infants,22	 meaning	 that	 faecal	 concentra‐
tions	may	 be	 high,	 or	 change	 over	 time,	 even	 in	 the	 absence	 of	
enteropathy.	It	is	likely	that	this	accounted	for	the	higher	levels	of	
this	protein	in	the	two	study	groups	when	they	were	compared	to	
infants	who	were	 predominantly	 fed	 preterm	 formula.19,20,23	 For	
example,	 Sivan	 et	 al23	 reported	 concentrations	 of	 faecal	 alpha‐1	
antitrypsin	in	a	sample	of	preterm	infants	who	were	predominantly	
fed	 formula.	These	 ranged	 from	0.34	 to	1.05	mg/g	stools,	which	
was	lower	than	the	geometric	mean	values	observed	in	our	study	
(Figure	2).	However,	it	is	unlikely	that	the	alpha‐1	antitrypsin	con‐
tent	 of	 human	milk	 contributed	 to	 the	 small,	 but	 significant,	 dif‐
ference	 between	 the	 groups	 on	 study	 day	 21,	 since	 each	 group	
consumed	a	very	similar	volume	of	fortified	milk	during	the	study	
period.	This	was	153	mL/kg/d	in	both	groups,	with	49%	of	the	vol‐
ume	 from	 donor	milk	 in	 the	 new	 fortifier	 group	 and	 51%	 in	 the	
control	 fortifier	 group.15	 Alternatively,	 it	 can	 be	 speculated	 that	
these	 results	 indicate	a	 slight,	but	 significant,	 increase	 in	gastro‐
intestinal	protein	 loss	and,	or,	 inflammation	among	 infants	 in	 the	
control	 than	new	 fortifier	 groups.	However,	 the	geometric	mean	
concentrations	 in	 both	 groups	were	 substantially	 lower	 than	 the	





faecal	 calprotectin	has	also	been	 shown	 to	be	higher	 in	healthy,	
exclusively	breastfed	infants	than	in	infants	fed	formula	or	a	mix‐
ture	of	breast	milk	and	formula,26,27	suggesting	that	higher	levels	









not	 show	 this	 increase	over	 time.	Together,	 these	previous	 find‐
ings	 suggest	 that	 faecal	 calprotectin	 may	 not	 always	 represent	
pathological	 inflammation	 in	 preterm	 infants,	 but	 rather	 feed‐
ing	pattern	and,	or,	normal	maturation	of	the	gut	 immune	axis.28 
Furthermore,	 no	 infants	 in	 our	 study	 experienced	 NEC,	 despite	
the	fact	 that	many	had	calprotectin	 levels	 (ie	median	 [Q1‐Q3]	of	
296	[136‐565]	μg/g	stools	 in	both	groups	combined	at	study	day	
21)	that	greatly	exceeded	those	reported	to	be	 indicative	of	this	






in	 this	 biomarker	 prior	 to	 commencing	 fortification	 or	 14	 days	
after	fortification	with	either	a	human	milk	or	bovine	milk‐based	




Reduced	 elastase‐1	 secretion	 in	 stools	 is	 considered	 to	 be	 a	
marker	of	pancreatic	insufficiency,	with	values	of	less	than	200	μg/g	
stools	 indicating	 impaired	 exocrine	 pancreatic	 function.31	 Values	




























protectin	 threshold	 value	 for	 early	 detection	 of	 NEC	 should	 be	
revised	 in	 light	of	 the	 relatively	high	concentrations	observed	 in	
our	subjects.	When	they	are	combined	with	previously	 reported	
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anthropometry	 and	 clinical	 biochemistry	 data,	 these	 results	 fur‐
ther	 illustrate	 that	 the	new	 fortifier	was	 safe	 and	well	 tolerated	
by	our	cohort.
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